Stifel Nicolaus Reaffirms Buy Rating for Janux Therapeutics (NASDAQ:JANX)

Key Points

• Stifel Nicolaus has reaffirmed a buy rating for Janux Therapeutics with a target price of $45.00, indicating a potential upside of 89.23% from the recent stock close.
• Multiple investment firms have given mixed ratings for Janux Therapeutics, with an average rating of buy and a consensus price target of $79.18.
• Janux Therapeutics is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer through innovative platforms, with two candidates currently in Phase 1 clinical trials.

Janux Therapeutics (NASDAQ:JANX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Stifel Nicolaus in a research note issued on Wednesday,Benzinga reports. They currently have a $45.00 target price on the stock. Stifel Nicolaus' price objective would indicate a potential upside of 89.23% from the company's previous close.

JANX has been the subject of several other reports. Guggenheim assumed coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They issued a "buy" rating and a $72.00 price target for the company. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Piper Sandler began coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $79.18.

Janux Therapeutics Stock Performance

JANX stock opened at $23.78 on Wednesday. Janux Therapeutics has a 1 year low of $21.97 and a 1 year high of $71.71. The stock's 50 day moving average price is $24.57 and its 200 day moving average price is $26.51. The firm has a market cap of $1.43 billion, a P/E ratio of -13.21 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). On average, research analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of JANX. Osaic Holdings Inc. grew its position in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after purchasing an additional 3,037 shares during the last quarter. Squarepoint Ops LLC lifted its position in shares of Janux Therapeutics by 230.0% during the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company's stock worth $4,379,000 after purchasing an additional 132,121 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock worth $91,000 after purchasing an additional 2,502 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Janux Therapeutics by 64.8% during the second quarter. Lazard Asset Management LLC now owns 99,858 shares of the company's stock worth $2,306,000 after buying an additional 39,278 shares during the last quarter. Finally, Engineers Gate Manager LP increased its stake in Janux Therapeutics by 115.0% in the second quarter. Engineers Gate Manager LP now owns 39,749 shares of the company's stock valued at $918,000 after purchasing an additional 21,258 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.